This transaction
Acquisition of shares and conversion into a subsidiaryDevelopment, manufacture, sale, import and export of medical devices for the otolaryngology and head and neck surgery fields
The impact of this transaction on results for the current fiscal year is expected to be immaterial, but over the medium to long term, it is expected to contribute to increasing the corporate value of the Group.
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares and conversion into a subsidiary |
| Counterparty name | 永島ホールディングス株式会社 |
| Name of the Subject Company | 永島医科器械株式会社 |
| Business Description of the Subject Company | Development, manufacture, sale, import and export of medical devices for the otolaryngology and head and neck surgery fields |
| Location of the Subject Company | Bunkyo-ku, Tokyo |
| Capital Stock of the Subject Company | ¥95 million |
| Date of Establishment of the Subject Company | February 1937 |
| Net Sales of the Subject Company | ¥2,676 million (fiscal year ended June 2025) |
| Number of shares acquired | All shares (number of shares and voting rights: Not disclosed) |
| Impact on Business Performance | The impact of this transaction on results for the current fiscal year is expected to be immaterial, but over the medium to long term, it is expected to contribute to increasing the corporate value of the Group. |
| Contract Date | 27 May 2026 |
| Execution Date / Effective Date | Share acquisition completion date: To be determined |
| Management structure after acquisition | The name and head office location of 永島医科器械 are not scheduled to change. The treatment of its representative and employees is Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition is intended to incorporate 永島医科器械's product development capabilities and expertise in specialized fields, expand the Group's manufacturing and development functions and in-house product lineup in the medical device business, increase sales opportunities through collaboration with its wholesale business for prescription pharmaceuticals and other products, and strengthen competitiveness.